Qiagen to acquire U.K. firm that makes genetic tests

09/22/2009 | Forbes

German firm Qiagen said it agreed to acquire DxS, a U.K.-based maker of genetic tests, in an effort to broaden its cancer diagnostics business. The deal entitles DxS to receive $95 million in cash from Qiagen and up to $35 million in additional payments if certain milestones are met.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care